« Back to Record
Eiger, D., Maurer, C., Brandão, M., Aftimos, P., Punie, K., Taylor, D., Van den Mooter, T., Poncin, R., Canon, J.-L., Duhoux, F. P., Casert, V., Clatot, F., Velghe, C., Craciun, L., Paesmans, M., de Azambuja, E., Ignatiadis, M., Larsimont, D., Piccart-Gebhart, M., & Buisseret, L. (2020). 348P First findings from SYNERGY, a phase I/II trial testing the addition of the anti-CD73 oleclumab (O) to the anti-PD-L1 durvalumab (D) and chemotherapy (ChT) as first line therapy for patients (pts) with metastatic triple-negative breast cancer (mTNBC). Annals of oncology, 31, S386-S387. doi:10.1016/j.annonc.2020.08.450
Citation APA
Permalink
Permalink
http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/401772



